Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy
NCT03636958 · Assistance Publique Hopitaux De Marseille · NA · withdrawn · last registry update 2022-06-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “concomitant decision of the sponsor and the PI, lack of patients” | – | Registry record, Assistance Publique Hopitaux De Marseille |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GRIA4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-06-22Results posted on the registry: Mayo Clinic, Anticonvulsant Agent + Perampanel (NCT04650204)
- 2023-06-22Also stopped (terminated): Mayo Clinic, Anticonvulsant Agent + Perampanel (NCT04650204)
- 2023-06-22Results posted on the registry: Mayo Clinic, Phentermine-Topiramate Extended Release + Placebo (NCT04408586)
- 2023-05-06Also stopped (terminated): Stony Brook University, Perampanel + Placebo Oral Tablet (NCT03020797)
- 2023-03-23Results posted on the registry: VA Office of Research and Development, Topiramate + placebo (NCT03018704)
- 2023-03-23Also stopped (terminated): VA Office of Research and Development, Topiramate + placebo (NCT03018704)
- 2023-02-28Phase 3 first posted: AbbVie, Atogepant + Placebo for Atogepant (NCT05748483)
- 2023-02-14Also stopped (terminated): Hartford Hospital, Administration of weight loss drug (Metformin or Topiramate) (NCT03603080)
- 2022-10-07Results posted on the registry: Virginia Commonwealth University, Perampanel Tablet + Disulfiram (NCT04502589)
- 2022-09-10Results posted on the registry: VIVUS LLC, VI-0521 oral capsule + Placebo oral capsule (NCT03922945)
- 2022-07-13Results posted on the registry: University of Colorado, Denver, Topiramate (NCT03335163)
- 2022-05-16Results posted on the registry: Eisai Inc., Perampanel (NCT03288129)
- 2022-03-09Results posted on the registry: Eisai Inc., Placebo + Perampanel (NCT02834793)
- 2022-03-09Also stopped (terminated): Eisai Inc., Placebo + Perampanel (NCT02834793)
- 2022-03-03Also stopped (terminated): University of Maryland, Baltimore, Topiramate + Placebo (NCT01408641)
- 2022-03-02Phase 3 first posted: University of Southern Denmark, Rapid sedation (NCT05263674)
- 2022-01-27Phase 3 first posted: Eurofarma Laboratorios S.A., ADF1 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 75mg + ADF2 Group Eurofarma drug association of Sibutramine IR 15mg / Topiramate XR 100mg (NCT05209984)
- 2021-12-08Results posted on the registry: University of Arizona, Perampanel Oral Tablet (NCT03457129)
- 2021-09-01Also stopped (terminated): American University of Beirut Medical Center, Fycompa (NCT03377309)
- 2021-08-09Results posted on the registry: Novartis Pharmaceuticals, Erenumab + Topiramate (NCT03828539)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision